TNF-mediated inflammatory disease

被引:1515
作者
Bradley, J. R. [1 ]
机构
[1] Addenbrookes Hosp, NIHR Cambridge Biomed Res Ctr, Cambridge CB2 2QQ, England
关键词
tumour necrosis factor; signal transduction; inflammation; infection; arthritis; therapy;
D O I
10.1002/path.2287
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
TNF was originally described as a circulating factor that can cause necrosis of tumours, but has since been identified as a key regulator of the inflammatory response. This review describes the known signalling pathways and cell biological effects of TNF, and our understanding of the role of TNF in human disease. TNF interacts with two different receptors, designated TNFR1 and TNFR2, which are differentially expressed on cells and tissues and initiate both distinct and overlapping signal transduction pathways. These diverse signalling cascades lead to a range of cellular responses, which include cell death, survival, differentiation, proliferation and migration. Vascular endothelial cells respond to TNF by undergoing a number of pro-inflammatory changes, which increase leukocyte adhesion, transendothelial migration and vascular leak and promote thrombosis. The central role of TNF in inflammation has been demonstrated by the ability of agents that block the action of TNF to treat a range of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease and psoriasis. The increased incidence of infection in patients receiving anti-TNF treatment has highlighted the physiological role of TNF in infectious diseases. Copyright (C) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:149 / 160
页数:12
相关论文
共 148 条
[1]   FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase [J].
AdamKlages, S ;
Adam, D ;
Wiegmann, K ;
Struve, S ;
Kolanus, W ;
SchneiderMergener, J ;
Kronke, M .
CELL, 1996, 86 (06) :937-947
[2]  
AKOBENG AK, COCHRANE DATABASE SY
[3]   TNFR1-and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury [J].
Al-Lamki, RS ;
Wang, J ;
Vandenabeele, P ;
Bradley, JA ;
Thiru, S ;
Luo, DH ;
Min, W ;
Pober, JS ;
Bradley, JR .
FASEB JOURNAL, 2005, 19 (12) :1637-1645
[4]   Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants [J].
Al-Lamki, RS ;
Wang, J ;
Skepper, JN ;
Thiru, S ;
Pober, JS ;
Bradley, JR .
LABORATORY INVESTIGATION, 2001, 81 (11) :1503-1515
[5]  
[Anonymous], 1999, Neurology, V53, P457
[6]   Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].
Antoni, CE ;
Kavanagh, A ;
Kirkham, B ;
Tutuncu, Z ;
Burmester, GR ;
Schneider, U ;
Furst, DE ;
Molitor, J ;
Keystone, E ;
Gladman, D ;
Manger, B ;
Wassenberg, S ;
Weier, R ;
Wallace, DJ ;
Weisman, MH ;
Kalden, JR ;
Smolen, J .
ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236
[7]   TNFα promotes proliferation of oligodendrocyte progenitors and remyelination [J].
Arnett, HA ;
Mason, J ;
Marino, M ;
Suzuki, K ;
Matsushima, GK ;
Ting, JPY .
NATURE NEUROSCIENCE, 2001, 4 (11) :1116-1122
[8]   Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab [J].
Baraliakos, X ;
Listing, J ;
Rudwaleit, M ;
Brandt, J ;
Sieper, J ;
Braun, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1462-1466
[9]  
Baraliakos X, 2007, J RHEUMATOL, V34, P510
[10]   Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement [J].
Baughman, Robert P. ;
Drent, Marjolein ;
Kavuru, Mani ;
Judson, Marc A. ;
Costabel, Ulrich ;
du Bois, Roland ;
Albera, Carlo ;
Brutsche, Martin ;
Davis, Gerald ;
Donohue, James F. ;
Mueller-Quernheim, Joachim ;
Schlenker-Herceg, Rozsa ;
Flavin, Susan ;
Lo, Kim Hung ;
Oemar, Barry ;
Barnathan, Elliot S. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (07) :795-802